论文部分内容阅读
目的探析系统性红斑狼疮采用环磷酰胺与人免疫球蛋白联合治疗对患者血清单核细胞趋化蛋白4(MCP-4)及白细胞介素-4(IL-4)的影响效果。方法 78例系统性红斑狼疮患者为研究对象,根据电脑随机法将其分为对照组和观察组,各39例。对照组给予常规治疗,观察组则运用环磷酰胺与人免疫球蛋白联合治疗,比较两组治疗效果。结果治疗前,两组的IL-4和MCP-4水平比较,差异无统计学意义(P>0.05)。连续治疗4周后,观察组的治疗总有效率为94.88%,高于对照组的74.36%,差异有统计学意义(P<0.05)。观察组的血清IL-4和MCP-4、24 h尿蛋白水平与系统性红斑狼疮疾病活动指数(SLEDAI)评分均低于对照组,差异有统计学意义(P<0.05)。结论临床上给予系统性红斑狼疮患者人免疫球蛋白与环磷酰胺联合治疗,可以使血清MCP-4和IL-4水平降低,使Th1和Th2细胞免疫平衡恢复,有助于提高治疗效果。
Objective To investigate the effect of combined treatment of cyclophosphamide and human immunoglobulin on serum monocyte chemoattractant protein 4 (MCP-4) and interleukin-4 (IL-4) in patients with systemic lupus erythematosus. Methods A total of 78 patients with systemic lupus erythematosus (SLE) were enrolled in this study. They were divided into control group and observation group according to the computer randomized method, with 39 cases in each group. The control group was given routine treatment, while the observation group was treated with cyclophosphamide combined with human immunoglobulin. The therapeutic effect was compared between the two groups. Results Before treatment, there was no significant difference between the two groups in the levels of IL-4 and MCP-4 (P> 0.05). After continuous treatment for 4 weeks, the total effective rate of the observation group was 94.88%, which was higher than that of the control group (74.36%), the difference was statistically significant (P <0.05). The levels of serum IL-4, MCP-4, 24 h urinary protein and SLEDAI in the observation group were lower than those in the control group, the difference was statistically significant (P <0.05). Conclusions Combined administration of immunoglobulin and cyclophosphamide in patients with systemic lupus erythematosus can decrease the levels of serum MCP-4 and IL-4, and restore the immune balance of Th1 and Th2 cells, which may help to improve the therapeutic effect.